COEP (Coeptis Therapeutics Holdings) Net Margin %: -183.06% (As of Dec. 2025)


COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings Net Margin %?

Coeptis Therapeutics Holdings COEP +1.52% 12 Net Margin % is -183.06% as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100. Among 947 Biotechnology companies, Coeptis Therapeutics Holdings ranks worse than 76.35% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Coeptis Therapeutics Holdings's Net Income for the three months ended in Dec. 2025 was $-1.58 Mil. Coeptis Therapeutics Holdings's Revenue for the three months ended in Dec. 2025 was $0.86 Mil. Therefore, Coeptis Therapeutics Holdings's net margin for the quarter that ended in Dec. 2025 was -183.06%.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Net Margin % or its related term are showing as below:

COEP' s Net Margin % Range Over the Past 10 Years
Min: -29535.48   Med: -17932   Max: -800.44
Current: -800.44

COEP's Net Margin % is ranked worse than
76.35% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs COEP: -800.44

Coeptis Therapeutics Holdings  (NAS:COEP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Coeptis Therapeutics Holdings Net Margin % Related Terms

Coeptis Therapeutics Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings Net Margin % Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -17,932.00 0.00 0.00 0.00 -874.32

Coeptis Therapeutics Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -4,853.97 -1,758.71 -1,155.70 -183.06

COEP vs ANIX, COYA, PMN: Net Margin % Comparison

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coeptis Therapeutics Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Net Margin % falls into.


COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coeptis Therapeutics Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Coeptis Therapeutics Holdings's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-11.917/1.363
=-874.32 %

Coeptis Therapeutics Holdings's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.578/0.862
=-183.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -183.06% mean?
Coeptis Therapeutics Holdings (COEP) has a Net Margin % of -183.06% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. According to the industry distribution chart, Coeptis Therapeutics Holdings ranks #723 out of 947 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Coeptis Therapeutics Holdings' Net Margin % too high?
Coeptis Therapeutics Holdings' current Net Margin % is -183.06%. Based on the distribution chart, Coeptis Therapeutics Holdings ranks #723 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' Net Margin % compare to ANIX and COYA?
According to the Biotechnology industry distribution chart, Coeptis Therapeutics Holdings ranks #723 out of 947 companies for Net Margin %. This places Coeptis Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current Net Margin % is -183.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current Net Margin % of -183.06%. The current Net Margin % is -183.06%. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current Net Margin % is -183.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price